This narrative review covers the expanding landscape of incretin-based peptide therapies, from single GLP-1 receptor agonists through dual GLP-1/GIP agonists (tirzepatide) to emerging triple GLP-1/GIP/glucagon receptor agonists, discussing mechanisms, receptor desensitization, and future therapeutic potential.
From single to triple agonismThe evolution from GLP-1-only drugs to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists represents the cutting edge of peptide-based metabolic therapy
What the researchers found
GLP-1 RAs may face efficacy plateaus due to receptor desensitization. Tirzepatide's dual GLP-1/GIP agonism offers superior weight loss and glycemic control. Triple agonists (GLP-1/GIP/glucagon) represent the next frontier. Oral GLP-1 formulations are expanding access. Understanding intercellular signaling and inflammatory pathways is key to developing next-generation agents.
Why it matters
The GLP-1 drug revolution is just beginning. This review contextualizes where we are — from established single agonists to the frontier of triple agonists — and addresses the critical question of whether receptor desensitization limits long-term efficacy, a concern for patients on lifelong therapy.
The numbers in context
Review covers GLP-1 RAs, dual GIP/GLP-1 agonists (tirzepatide), triple agonists (GLP-1/GIP/glucagon), and amylin-based therapies.
How the study worked
Narrative review covering published clinical trials, mechanistic studies, and emerging drug pipeline data on incretin-based peptide therapies for obesity and type 2 diabetes.
Who was studied
Adults with obesity and/or type 2 diabetes
What this study cannot tell us
Narrative review with inherent selection bias in study inclusion. Doesn't provide quantitative meta-analytic synthesis. Triple agonist data is mostly preclinical or early-phase. Long-term desensitization concerns are theoretical rather than conclusively demonstrated in large trials.
How to read the evidence
Rated moderate: narrative review covering strong trial evidence for approved drugs but speculative for pipeline compounds. No systematic methodology.
When this study was published
Published in 2024. Captures the current state of the rapidly evolving incretin drug landscape.
The bigger picture
The peptide drug pipeline for metabolic diseases is the most active in pharmaceutical history. Understanding the rationale for multi-receptor agonism and the challenges of receptor desensitization is essential for clinicians, researchers, and patients navigating this rapidly changing landscape.
Questions still open
- Does receptor desensitization actually limit GLP-1 RA efficacy in long-term clinical use, or do compensatory mechanisms prevent this?
- Will triple agonists provide clinically meaningful advantages over dual agonists like tirzepatide?
- How will oral GLP-1 formulations change the treatment landscape compared to injectable forms?
Common questions
What's the difference between single, dual, and triple receptor agonists for weight loss?
Do GLP-1 drugs become less effective over time?
Read the original research
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.
Biomedicines, 12(6)
Citation
Sztanek, Ferenc; Tóth, László Imre; Pető, Attila; Hernyák, Marcell; Diószegi, Ágnes; Harangi, Mariann. (2024). New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.. Biomedicines, 12(6). https://doi.org/10.3390/biomedicines12061320